Developer docs
API playgroundTry for free, no card

Search company profiles

Curapath

Full company profile

uuid0006ae8

Namestring
Curapath
Legal namestring
Polypeptide Therapeutic Solutions S.L.
Websiteurl
curapath.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Curapath (legal entity: Polypeptide Therapeutic Solutions S.L.) is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Paterna, Valencia, Spain, with a US commercial office in Cambridge, MA. Founded in 2013 and rebranded from PTS (Polypeptide Therapeutic Solutions) to Curapath, the company specializes in non-viral drug delivery systems based on lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), and polymer-drug conjugates, serving biotech and pharmaceutical companies developing RNA therapeutics, gene therapies, mRNA vaccines, and advanced biologics. Its proprietary technology stack includes STAR-CXP polyaminoacid transfection polymers (reportedly delivering up to 9x higher transfection efficiency than jetPEI) and Polysarcosine (PSar), a PEG-free stealth shielding polymer positioned as a lower-immunogenicity alternative to PEGylation.

The company offers end-to-end CDMO services spanning pre-clinical process development, GMP clinical supply manufacturing, and commercial-scale production, backed by AEMPS Authorization Number 6754E for manufacturing investigational medicinal products and a track record of 250+ GMP batches released with 100% compliance. Curapath monetizes through two streams: (1) professional services CDMO contracts with phase-appropriate pricing from preclinical through commercial GMP production, and (2) a product catalog selling proprietary and reference polymer/lipid excipients, ionizable lipids, shielding lipids, and nanoparticle components for research and GMP use. Go-to-market is B2B enterprise field sales supported by technical subject matter experts, with customer acquisition driven by industry events (ASCGT, TIDES USA), a technical resource library, the NanoTalks blog, and direct relationship management. The company reports an NPS of 61 measured by Hubspot in 2024, with customer testimonials concentrated among startup and mid-sized biotech clients including Elastrin Therapeutics, GenEdit, Iris Biotech, Macro Biologics, BioDevek, KNAUER, SYNGOI, and Orphatrade.

Curapath operates in markets projected at $5.8B (pharmaceutical lipids, 2026, growing at 5.0% CAGR to $9.4B by 2036) and $420.2B (nanobiotechnology by 2034, 9.37% CAGR). Leadership is headed by CEO Philippe Clavel, with Juan José Arroyo serving as Head of Project Management Office. The company has no disclosed funding rounds, no M&A activity, and no identified institutional investors in the source data.

Short descriptiontext

Curapath is a Spain-based CDMO specializing in non-viral drug delivery systems, including lipid nanoparticles, polymer nanoparticles, and polymer-drug conjugates. It serves biotech and pharma companies developing RNA therapeutics, gene therapies, and advanced biologics from preclinical through commercial GMP manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPaterna, Spain
HQ citystring
Paterna
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, lipid nanoparticles, polymer nanoparticles, non-viral drug delivery, GMP manufacturing services
Industry3 codes
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code5 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Nanotechnology541713
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Services (Contract Manufacturing)
TypeProfessional Services
Description

Phase-appropriate contract development and manufacturing services from preclinical through commercial GMP production, including process development, analytical methods, formulation, and batch certification for polymer and lipid-based drug delivery systems.

curapath.com
2Product Catalog (Excipients and Reagents)
TypeOne Time License
Description

Sale of proprietary and reference polymer and lipid excipients, ionizable lipids, shielding lipids, polymers, and nanoparticle components for research, preclinical, and GMP applications.

curapath.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1NanoTalks
Description

Curapath's blog magazine covering latest trends and practices in non-viral vectors and nanobiotechnology.

resources.curapath.com
+1 more record
Core offering1 text field

Curapath is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for polymer and lipid-based non-viral drug delivery systems. The company offers preclinical development through commercial-scale GMP manufacturing of lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer-drug conjugates, and functional excipients. It also sells a proprietary catalog of ionizable lipids, shielding polymers, and excipients for research and clinical applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NPS of 61 reflecting high customer satisfaction
+2 more records
Product overview1 text field

Curapath is a science-driven Contract Development and Manufacturing Organization (CDMO) specializing in polymer and lipid-based non-viral drug delivery systems. The company operates as an integrated platform with two core delivery technologies—Lipid Nanoparticles (LNPs) and Polymer Nanoparticles (PNPs)—complemented by extensive component portfolios including ionizable lipids, shielding lipids, ionizable cationic polymers, shielding polymers (notably Polysarcosine as a PEG-free alternative), and polymer-drug conjugates. Curapath provides end-to-end services spanning pre-clinical development (formulation screening, process development, pilot manufacturing), clinical supply (GMP production, IND/IMPD packages, batch certification), and commercial manufacturing (validation, regulatory support). The platform is supported by comprehensive analytical methods for LNP and PNP characterization. Recent innovations include STAR-CXP polyaminoacid transfection polymers, lipid-polymer hybrid nanoparticles (LPHNs), and the next-generation LNP formulation developed in partnership with Certest.

Product and service16 records
1Lipid Nanoparticles (LNPs)
CategoryDrug Delivery Platform
2Polymer Nanoparticles (PNPs)
CategoryDrug Delivery Platform
3STAR-CXP Polyaminoacid Polymers
CategoryPolymer Excipient Product
4Polymer-Drug Conjugates
CategoryPolymer Excipient Product
5Ionizable Lipids
CategoryLipid Excipient Product
6Shielding Lipids
CategoryLipid Excipient Product
7Ionizable Cationic Polymers
CategoryPolymer Excipient Product
8Shielding Polymers
CategoryPolymer Excipient Product
9Polysarcosine (PSar)
CategoryPolymer Excipient Product
10Curapath Product Catalog
CategoryProduct Catalog
11Pre-Clinical Development Services
CategoryCDMO Service
12Clinical Supply Services
CategoryCDMO Service
13Commercial Manufacturing Services
CategoryCDMO Service
14Analytical Methods Services
CategoryCDMO Service
15LNP/PNP Formulation Services
CategoryCDMO Service
16Bio-Conjugation Services
CategoryCDMO Service
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-17
Description

Certest and Curapath have joined forces to develop a novel LNP formulation leveraging the complementary benefits of their proprietary excipients. This collaboration combines Certest's diagnostic and testing capabilities with Curapath's lipid nanoparticle formulation expertise for next-generation LNP development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration with Professor Tim J. Deming in bioengineering, recognizing Curapath's depth of understanding and level of expertise in polypeptide manufacturing and analytics.

3Universitat Jaume I
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partnership with BIOSUPRAMAT research group led by Dr. Beatriu Escuder, positioning Curapath as an ideal partner for transferring fundamental research into market applications.

curapath.com
Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Acuitas is a specialist LNP technology company providing ionizable lipid and LNP formulation development, with deep partnerships in mRNA vaccine and therapeutic delivery. It is the closest direct comparable to Curapath's LNP formulation and manufacturing business.

TypeDirect peer
Description

Genevant develops lipid nanoparticle delivery systems for RNA therapeutics and has commercial LNP partnerships across the industry. It competes head-to-head with Curapath in non-viral nucleic acid delivery CDMO services.

TypeBroad incumbent
Description

CordenPharma is a global CDMO with established lipid and peptide manufacturing capabilities, including LNP formulation services. It is a broader incumbent competitor with deeper resources and a wider service portfolio.

4Evonik (Health Care)
TypeBroad incumbent
Description

Evonik operates a CDMO business that includes lipid excipients and polymer-based drug delivery systems. It is a diversified chemical and CDMO incumbent with overlapping capabilities in functional excipients and nanoparticle formulation.

TypeDirect peer
Description

Polypeptide Group is a specialized CDMO focused on peptide and polypeptide API manufacturing. It shares Curapath's heritage (Curapath was formerly PTS Polypeptide Therapeutic Solutions) and operates in adjacent polymer/peptide drug delivery manufacturing.

TypeEmerging player
Description

Vernal Biosciences is an emerging CDMO specializing in mRNA and LNP formulation services for clinical-stage developers. It is comparable to Curapath as a smaller specialist targeting the same LNP manufacturing niche.

TypeBroad incumbent
Description

BioNTech operates in-house LNP manufacturing capabilities (via its Polymun Scientific acquisition) for mRNA therapeutics. It is a broad incumbent that both competes with and represents the kind of internal capacity that Curapath's clients may opt to build.

TypeBroad incumbent
Description

PCI Pharma Services is a global CDMO offering injectable and complex formulation manufacturing, with growing capabilities in lipid-based drug delivery. It is a broader incumbent alternative for biotech clients evaluating CDMO partners.

TypeEmerging player
Description

Ascendia Pharma is a specialty CDMO providing formulation development and manufacturing for poorly soluble and complex drug products, including nanoemulsions and lipid-based systems. It is an emerging player with comparable complex formulation capabilities.

TypeOthers
Description

Tune Therapeutics is a developer of epigenetic gene-editing therapeutics using non-viral delivery. While not a CDMO, it is a representative buyer of specialized non-viral delivery CDMO services and a relevant ecosystem comparable.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curapath

Pharmaceutical Contract Development and Manufacturing (CDMO)curapath.com

Curapath is a Spain-based CDMO specializing in non-viral drug delivery systems, including lipid nanoparticles, polymer nanoparticles, and polymer-drug conjugates. It serves biotech and pharma companies developing RNA therapeutics, gene therapies, and advanced biologics from preclinical through commercial GMP manufacturing.

What Curapath does

Curapath (legal entity: Polypeptide Therapeutic Solutions S.L.) is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Paterna, Valencia, Spain, with a US commercial office in Cambridge, MA. Founded in 2013 and rebranded from PTS (Polypeptide Therapeutic Solutions) to Curapath, the company specializes in non-viral drug delivery systems based on lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), and polymer-drug conjugates, serving biotech and pharmaceutical companies developing RNA therapeutics, gene therapies, mRNA vaccines, and advanced biologics. Its proprietary technology stack includes STAR-CXP polyaminoacid transfection polymers (reportedly delivering up to 9x higher transfection efficiency than jetPEI) and Polysarcosine (PSar), a PEG-free stealth shielding polymer positioned as a lower-immunogenicity alternative to PEGylation.

The company offers end-to-end CDMO services spanning pre-clinical process development, GMP clinical supply manufacturing, and commercial-scale production, backed by AEMPS Authorization Number 6754E for manufacturing investigational medicinal products and a track record of 250+ GMP batches released with 100% compliance. Curapath monetizes through two streams: (1) professional services CDMO contracts with phase-appropriate pricing from preclinical through commercial GMP production, and (2) a product catalog selling proprietary and reference polymer/lipid excipients, ionizable lipids, shielding lipids, and nanoparticle components for research and GMP use. Go-to-market is B2B enterprise field sales supported by technical subject matter experts, with customer acquisition driven by industry events (ASCGT, TIDES USA), a technical resource library, the NanoTalks blog, and direct relationship management. The company reports an NPS of 61 measured by Hubspot in 2024, with customer testimonials concentrated among startup and mid-sized biotech clients including Elastrin Therapeutics, GenEdit, Iris Biotech, Macro Biologics, BioDevek, KNAUER, SYNGOI, and Orphatrade.

Curapath operates in markets projected at $5.8B (pharmaceutical lipids, 2026, growing at 5.0% CAGR to $9.4B by 2036) and $420.2B (nanobiotechnology by 2034, 9.37% CAGR). Leadership is headed by CEO Philippe Clavel, with Juan José Arroyo serving as Head of Project Management Office. The company has no disclosed funding rounds, no M&A activity, and no identified institutional investors in the source data.

Curapath firmographics

Firmographics
Name
Curapath
Legal name
Polypeptide Therapeutic Solutions S.L.
Website
https://curapath.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Curapath is a Spain-based CDMO specializing in non-viral drug delivery systems, including lipid nanoparticles, polymer nanoparticles, and polymer-drug conjugates. It serves biotech and pharma companies developing RNA therapeutics, gene therapies, and advanced biologics from preclinical through commercial GMP manufacturing.
Ownership category
akta.pro rank

Curapath industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Nanotechnology (541713)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Contract pharmaceutical manufacturing
  • Lipid nanoparticles
  • Polymer nanoparticles
  • Non-viral drug delivery
  • GMP manufacturing services

Where Curapath is headquartered

Location

Headquarters

HQ city
Paterna
HQ country
Spain
HQ region
Europe

Offices3 records

Markets served

Curapath business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CDMO Services (Contract Manufacturing): Phase-appropriate contract development and manufacturing services from preclinical through commercial GMP production, including process development, analytical methods, formulation, and batch certification for polymer and lipid-based drug delivery systems.
  2. Product Catalog (Excipients and Reagents): Sale of proprietary and reference polymer and lipid excipients, ionizable lipids, shielding lipids, polymers, and nanoparticle components for research, preclinical, and GMP applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Curapath product offering

Product offering

Core offering

Curapath is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for polymer and lipid-based non-viral drug delivery systems. The company offers preclinical development through commercial-scale GMP manufacturing of lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer-drug conjugates, and functional excipients. It also sells a proprietary catalog of ionizable lipids, shielding polymers, and excipients for research and clinical applications.

Product overview

Curapath is a science-driven Contract Development and Manufacturing Organization (CDMO) specializing in polymer and lipid-based non-viral drug delivery systems. The company operates as an integrated platform with two core delivery technologies—Lipid Nanoparticles (LNPs) and Polymer Nanoparticles (PNPs)—complemented by extensive component portfolios including ionizable lipids, shielding lipids, ionizable cationic polymers, shielding polymers (notably Polysarcosine as a PEG-free alternative), and polymer-drug conjugates. Curapath provides end-to-end services spanning pre-clinical development (formulation screening, process development, pilot manufacturing), clinical supply (GMP production, IND/IMPD packages, batch certification), and commercial manufacturing (validation, regulatory support). The platform is supported by comprehensive analytical methods for LNP and PNP characterization. Recent innovations include STAR-CXP polyaminoacid transfection polymers, lipid-polymer hybrid nanoparticles (LPHNs), and the next-generation LNP formulation developed in partnership with Certest.

Differentiator

Problem solved

Functional benefit

Brands

  • NanoTalks: Curapath's blog magazine covering latest trends and practices in non-viral vectors and nanobiotechnology.
  • STAR-CXP

Products and services

  • Lipid Nanoparticles (LNPs)
  • Polymer Nanoparticles (PNPs)
  • STAR-CXP Polyaminoacid Polymers
  • Polymer-Drug Conjugates
  • Ionizable Lipids
  • Shielding Lipids
  • Ionizable Cationic Polymers
  • Shielding Polymers
  • Polysarcosine (PSar)
  • Curapath Product Catalog
  • Pre-Clinical Development Services
  • Clinical Supply Services
  • Commercial Manufacturing Services
  • Analytical Methods Services
  • LNP/PNP Formulation Services
  • Bio-Conjugation Services

Quantifiable outcome

  • NPS of 61 reflecting high customer satisfaction
  • +2 more outcomes

Companies that use Curapath

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Curapath technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Curapath partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • CertestcoreStrategic or Co-development Partner · 17 March 2025Certest and Curapath have joined forces to develop a novel LNP formulation leveraging the complementary benefits of their proprietary excipients. This collaboration combines Certest's diagnostic and testing capabilities with Curapath's lipid nanoparticle formulation expertise for next-generation LNP development.
  • University of California Los Angeles (UCLA)minorStrategic or Co-development PartnerAcademic collaboration with Professor Tim J. Deming in bioengineering, recognizing Curapath's depth of understanding and level of expertise in polypeptide manufacturing and analytics.
  • Universitat Jaume IminorStrategic or Co-development PartnerAcademic partnership with BIOSUPRAMAT research group led by Dr. Beatriu Escuder, positioning Curapath as an ideal partner for transferring fundamental research into market applications.

Scale indicators4 records

Expansion highlights6 records

Curapath competitors and assessment

Company assessment

Direct peers

  • Acuitas Therapeutics: Acuitas is a specialist LNP technology company providing ionizable lipid and LNP formulation development, with deep partnerships in mRNA vaccine and therapeutic delivery. It is the closest direct comparable to Curapath's LNP formulation and manufacturing business.
  • Genevant Sciences: Genevant develops lipid nanoparticle delivery systems for RNA therapeutics and has commercial LNP partnerships across the industry. It competes head-to-head with Curapath in non-viral nucleic acid delivery CDMO services.
  • Polypeptide Group: Polypeptide Group is a specialized CDMO focused on peptide and polypeptide API manufacturing. It shares Curapath's heritage (Curapath was formerly PTS Polypeptide Therapeutic Solutions) and operates in adjacent polymer/peptide drug delivery manufacturing.

Broad incumbents

  • CordenPharma: CordenPharma is a global CDMO with established lipid and peptide manufacturing capabilities, including LNP formulation services. It is a broader incumbent competitor with deeper resources and a wider service portfolio.
  • Evonik (Health Care): Evonik operates a CDMO business that includes lipid excipients and polymer-based drug delivery systems. It is a diversified chemical and CDMO incumbent with overlapping capabilities in functional excipients and nanoparticle formulation.
  • BioNTech (Polymun Scientific): BioNTech operates in-house LNP manufacturing capabilities (via its Polymun Scientific acquisition) for mRNA therapeutics. It is a broad incumbent that both competes with and represents the kind of internal capacity that Curapath's clients may opt to build.
  • PCI Pharma Services: PCI Pharma Services is a global CDMO offering injectable and complex formulation manufacturing, with growing capabilities in lipid-based drug delivery. It is a broader incumbent alternative for biotech clients evaluating CDMO partners.

Emerging players

  • Vernal Biosciences: Vernal Biosciences is an emerging CDMO specializing in mRNA and LNP formulation services for clinical-stage developers. It is comparable to Curapath as a smaller specialist targeting the same LNP manufacturing niche.
  • Ascendia Pharma: Ascendia Pharma is a specialty CDMO providing formulation development and manufacturing for poorly soluble and complex drug products, including nanoemulsions and lipid-based systems. It is an emerging player with comparable complex formulation capabilities.

Others

  • Tune Therapeutics: Tune Therapeutics is a developer of epigenetic gene-editing therapeutics using non-viral delivery. While not a CDMO, it is a representative buyer of specialized non-viral delivery CDMO services and a relevant ecosystem comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Curapath social profiles

Digital presence

Curapath compliance and trust

Trust signal

Compliance3 records

Curapath financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curapath leadership team

Management profile

Number of profiles

Profiles3 records

Curapath funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curapath M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curapath

What does Curapath do?

Curapath is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for polymer and lipid-based non-viral drug delivery systems. The company offers preclinical development through commercial-scale GMP manufacturing of lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer-drug conjugates, and functional excipients. It also sells a proprietary catalog of ionizable lipids, shielding polymers, and excipients for research and clinical applications.

Is Curapath a public or private company?

Curapath is a private company. It is classified as unknown and is currently operating.

When was Curapath founded?

Curapath was founded in 2013. It employs 51 to 100 people.

Where is Curapath based?

Curapath is headquartered in Paterna, Spain, in the Europe region.

How does Curapath make money?

Two revenue lines are on record. CDMO Services (Contract Manufacturing) is the primary driver. The others are product Catalog (Excipients and Reagents).

Who are Curapath's main competitors?

Direct peers on record are Acuitas Therapeutics, Genevant Sciences and Polypeptide Group. Broad incumbents are CordenPharma, Evonik (Health Care), BioNTech (Polymun Scientific) and PCI Pharma Services. Emerging players are Vernal Biosciences and Ascendia Pharma. Tune Therapeutics is listed as an others.

Does Curapath have an API?

No public API is recorded for Curapath.

What industry is Curapath in?

Curapath's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 3254 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireCurapath and Nacalai Tesque Partner to Expand Access to next generation Polymers and PEG-Free Shielding Lipids in JapanCurapath and Nacalai Tesque partnered to distribute Curapath's PEG-free shielding lipids and polymers for lipid nanoparticle development in Japan. The materials, developed in Valencia, Spain, include active targeting lipids for extrahepatic delivery. The partnership aims to support Japanese researchers in advanced therapeutics.CurapathCurapath and Cristal Therapeutics Partner to Advance Next-Generation Targeted Drug Delivery with CliCr® Bioconjugation TechnologyCurapath and Cristal Therapeutics have entered into a co-exclusive license agreement to integrate Cristal's CliCr® bioconjugation technology into Curapath's drug delivery systems. Under this partnership, Curapath serves as the exclusive CDMO authorized to use the CliCr® platform for targeted nucleic acid delivery via polymer and lipid nanoparticles. This collaboration aims to enhance the precision and scalability of next-generation therapeutics targeting extrahepatic tissues.PR NewswireCayman Chemical and Curapath Partner to Provide Wider Access to PEG-Free Shielding Lipids for Lipid NanoparticlesCayman Chemical has partnered with Curapath to offer PEG-free shielding lipids for lipid nanoparticle (LNP) research, making Curapath's proprietary polysarcosine-based alternatives available through Cayman's global catalog and distribution network. The partnership addresses growing concerns about PEG-related immunogenicity in traditional shielding lipids, providing researchers with biocompatible, non-toxic alternatives for non-viral drug delivery, gene therapy, mRNA vaccines, and biologic therapies. Curapath's pSar shielding lipids are developed and manufactured at the company's headquarters in Valencia, Spain.CurapathAdvancing Peptide Delivery: Paving the Way for Next-Generation TherapiesThis article explores advances in peptide drug delivery systems, highlighting how nanoparticle-based delivery and bioconjugation strategies address challenges such as enzymatic degradation and limited cellular uptake. It uses semaglutide (commercialized by Novo Nordisk as Ozempic, Wegovy, and Rybelsus) as a case study for successful peptide therapeutics that overcome traditional limitations through structural modifications. The article promotes Curapath's expertise in developing nanoparticle platforms and bioconjugation techniques to enhance peptide stability, bioavailability, and targeted delivery for pharmaceutical applications.